

IIIa'

,

where Q and X are as defined in the first aspect and G^{LL} is a linker connected to a Ligand Unit; and

(iiib):



IIIb'

,

where R^{L1} and R^{L2} are as defined in the first aspect;

wherein p is an integer of from 1 to 20.

Disclosed herein is a conjugate of formula I:

$$L - (D^L)_p \qquad (I)$$

wherein L is a Ligand unit, D^L is a Drug Linker unit of formula I':



I'

wherein D, R^2, R^6, R^7, R^9, R^{11b}, Y, R", Y', D', $R^{6'}$, $R^{7'}$, $R^{9'}$ and R^{12}, including the presence or absence of double bonds between C2 and C3 and C2' and C3' respectively, are as defined herein;

wherein p is an integer from 1 to 20;

R^{LL} is a linker for connection to a cell binding agent, which is:



IIIa'

,

where Q and X are as defined herein and G^{LL} is selected from:

(G^{LL1-1})		(G^{LL6})	
(G^{LL1-2})		(G^{LL7})	
(G^{LL2})		(G^{LL8-1})	
(G^{LL3-1})		(G^{LL8-2})	
(G^{LL3-2})		(G^{LL9-1})	
(G^{LL4})		(G^{LL9-2})	
(G^{LL5})			

where Ar represents a C_{5-6} arylene group.

The Ligand unit, described more fully below, is a targeting agent that binds to a target moiety. The Ligand unit can, for example, specifically bind to a cell component (a Cell Binding Agent) or to other target molecules of interest. The Ligand unit can be, for example, a protein, polypeptide or peptide, such as an antibody, an antigen-binding fragment of an antibody, or other binding agent, such as an Fc fusion protein.

Disclosed herein is a composition comprising a mixture of conjugates as defined herein, wherein the average p in the mixture of conjugate compounds is about 1 to about 8.